First Penny Picks Is Taking a Look at a Hot Biotech Stock This Week: Rosetta Genomics (NASDAQ: ROSG)Elite Traders Group LLCMacReport Media
Rosettas stock is trading up 12.9% to $4.815 in recent trading.
Friday's Range: $4.29-$4.98
52-Week Range: $1.40-$23.43
Volume: 1.46 Million
Three-Month Average Volume: 1.71 Million
From a technical perspective, ROSG is surging higher here right off some near-term support at $4 with above-average volume. This move is quickly pushing ROSG within range of triggering a major breakout trade. That trade should hit once ROSG manages to take out some near-term overhead resistance levels at $5 to $5.35 with higher than average volume.
Traders should now look for long-biased trades in ROSG as long as it's trending above $4.53, and then once it sustains a move or close above those breakout levels with volume that hits near or above the 1.71 million average daily shares traded. If that breakout triggers soon, then ROSG will set up to re-test or possibly take out its next major overhead resistance levels at $6.35 to $7.70/share. (Get Free Analysis) http://www.firstpennypicks.com/get-your-free-research-report/
Comparable Biotech Industry Stocks Include: (KERX), (ITMN), (XOMA)
Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. Zerenex is also in Phase 2 development for the management of phosphorus and iron deficiency in anemic patients with Stage 3 to 5 non-dialysis dependent chronic kidney disease. (Get Free Analysis) http://www.firstpennypicks.com/get-your-free-research-report/
About InterMune (NASDAQ: ITMN), InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. In pulmonology, the company is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. Pirfenidone, the only medicine approved for IPF anywhere in the world, is approved for marketing by InterMune in the EU and Canada as Esbriet and is currently in a Phase 3 clinical trial to support regulatory registration in the United States. (Get Free Analysis) http://www.firstpennypicks.com/get-your-free-research-report/
XOMA Corporation (NASDAQ: XOMA) XOMA combines a portfolio of innovative therapeutic antibodies, both in late-stage clinical development and in preclinical research, with its recently launched commercial operations. XOMA focuses its antibody research and development on allosteric modulation, which offers opportunities for new classes of therapeutic antibodies to treat a wide range of human diseases. (Get Free analysis) http://www.firstpennypicks.com/get-your-free-research-report/
http://www.Firstpennypicks.com was developed as a <u>beacon of hope</u> in the penny stock newsletter industry. By not accepting compensation for our profiles we are able to offer a more interactive and trader friendly service in an industry full of biased advertisers. We know being caught at the tail end of a paid pump can be an expensive and tough lesson learned. Let our 20+ years of experience save you time and money.
For future updates and our weekly feature alerts subscribe free here:http://www.Firstpennypicks.com
Want To Increase Your Day Trading Profits By 50% Or More? Join our VIP Early Alert Membership For only $29.95/month:http://www.firstpennypicks.com/vip-membership/
<u>We do not accept compensation for any of the companies profiled in our Newsletter</u>
Please note that FirstPennyPicks.COM employees are not registered as an Investment Adviser in any jurisdiction whatsoever. This advertisement is for informational purposes only and is not intended to be a recommendation to buy or sell securities in any of the profiled companies listed here.
<u>READ AND COMPARE OUR FULL DISCLAIMER WITH ANY OTHER NEWSLETTER AT</u>http://www.firstpennypicks.com/disclaimer/
SOURCE: First Penny Picks